SOURCE: Innoviva

Innoviva

May 03, 2016 18:56 ET

Innoviva to Present at the Bank of America Merrill Lynch 2016 Health Care Conference on May 11

SOUTH SAN FRANCISCO, CA--(Marketwired - May 3, 2016) - Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Wednesday, May 11 at 8:40 a.m. PT, at the Wynn Las Vegas in Las Vegas.

The presentation will be webcast live and can be accessed from Innoviva's website at www.inva.com or from the following link: BofA ML Innoviva Webcast. A replay of the presentation will be available one hour after the presentation concludes through August 8, 2016.

About Innoviva
Innoviva, formerly known as Theravance, Inc., is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc. For more information, please visit Innoviva's website at www.inva.com.

ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.

(INVA-F)

Contact Information